公开(公告)号：US12109178B2

公开(公告)日：2024-10-08

申请号：US17821342

申请日：2022-08-22

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/138 ,  A61K9/00 ,  A61K31/137 ,  A61K31/485 ,  A61P25/24

CPC分类号： A61K31/138 ,  A61K9/0053 ,  A61K31/137 ,  A61K31/485 ,  A61P25/24

摘要： Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

公开(公告)号：US20240252451A1

公开(公告)日：2024-08-01

申请号：US18589348

申请日：2024-02-27

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/138 ,  A61K9/00 ,  A61K31/137 ,  A61K31/485 ,  A61P25/24

CPC分类号： A61K31/138 ,  A61K9/0053 ,  A61K31/137 ,  A61K31/485 ,  A61P25/24

摘要： Disclosed herein are methods of treating neurological or psychiatric diseases or disorders, such as nicotine addiction, using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.

公开(公告)号：US20240238276A1

公开(公告)日：2024-07-18

申请号：US18435115

申请日：2024-02-07

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/485 ,  A61K31/137 ,  A61P25/24

CPC分类号： A61K31/485 ,  A61K31/137 ,  A61P25/24

摘要： Disclosed herein are methods of treating neurological or psychiatric diseases or disorders, such as depression using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.

公开(公告)号：US20240066025A1

公开(公告)日：2024-02-29

申请号：US18495149

申请日：2023-10-26

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/485 ,  A61K9/20 ,  A61K9/24 ,  A61K31/137

CPC分类号： A61K31/485 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K31/137

摘要： This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients having mild or moderate hepatic impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

公开(公告)号：US20240024309A1

公开(公告)日：2024-01-25

申请号：US18475841

申请日：2023-09-27

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/485 ,  A61K31/135 ,  A61K31/137 ,  A61K31/15 ,  A61K31/343 ,  A61K31/381 ,  A61K9/00

CPC分类号： A61K31/485 ,  A61K31/135 ,  A61K31/137 ,  A61K31/15 ,  A61K31/343 ,  A61K31/381 ,  A61K9/0053

摘要： Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

公开(公告)号：US20240000771A1

公开(公告)日：2024-01-04

申请号：US18353323

申请日：2023-07-17

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/485 ,  A61K9/20 ,  A61K31/138

CPC分类号： A61K31/485 ,  A61K9/2086 ,  A61K9/2027 ,  A61K31/138

摘要： This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

公开(公告)号：US20230277504A1

公开(公告)日：2023-09-07

申请号：US17937948

申请日：2022-10-04

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/415 ,  A61K31/485

CPC分类号： A61K31/415 ,  A61K31/485

摘要： Neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound that inhibits the metabolism of dextromethorphan, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein.

公开(公告)号：US20230270740A1

公开(公告)日：2023-08-31

申请号：US18062273

申请日：2022-12-06

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/485 ,  A61K31/135 ,  A61K31/137 ,  A61K31/15 ,  A61K31/343 ,  A61K31/381 ,  A61K9/00

CPC分类号： A61K31/485 ,  A61K9/0053 ,  A61K31/15 ,  A61K31/135 ,  A61K31/137 ,  A61K31/343 ,  A61K31/381

摘要： Disclosed herein are methods of treating neurological or psychiatric diseases or disorders using a combination of an antidepressant, such as bupropion, and dextromethorphan. Related compositions and dosage forms are also described.

公开(公告)号：US20230225995A1

公开(公告)日：2023-07-20

申请号：US18188689

申请日：2023-03-23

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/138 ,  A61K9/00 ,  A61P25/24 ,  A61K31/137 ,  A61K31/485

CPC分类号： A61K31/138 ,  A61K9/0053 ,  A61P25/24 ,  A61K31/137 ,  A61K31/485

摘要： Disclosed herein are methods of treating neurological or psychiatric diseases or disorders using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.

公开(公告)号：US20230142244A1

公开(公告)日：2023-05-11

申请号：US18056848

申请日：2022-11-18

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/138 ,  A61K31/485 ,  A61K31/137 ,  A61P25/24 ,  A61K9/00

CPC分类号： A61K31/138 ,  A61K31/485 ,  A61K31/137 ,  A61P25/24 ,  A61K9/0053

摘要： Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.